Literature DB >> 9149128

The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation.

J Bentley1, D M Quinn, R S Pitman, J R Warr, G L Kellett.   

Abstract

We have previously shown that the hypersensitivity of KB MDR cells to 2-deoxy-D-glucose is associated with diminished plasma membrane GLUT-1 levels compared with parental, non-MDR cells. Here we report that MDR cells are hypersensitive to the N-linked glycosylation inhibitor tunicamycin, which induces partial inhibition of GLUT-1 glycosylation and diminishes GLUT-1-mediated transport. The effect of tunicamycin, which also enhances the hypersensitivity of MDR cells to 2-deoxy-D-glucose, could not be attributed to alterations in P-glycoprotein activity. The use of agents that act synergistically to diminish the level and activity of GLUT-1 in MDR cells may be of clinical potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149128     DOI: 10.1016/s0304-3835(97)04739-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

Review 2.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 3.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

4.  Identification of compounds selectively killing multidrug-resistant cancer cells.

Authors:  Dóra Türk; Matthew D Hall; Benjamin F Chu; Joseph A Ludwig; Henry M Fales; Michael M Gottesman; Gergely Szakács
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 5.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

6.  Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5.

Authors:  D A Greer; S Ivey
Journal:  Biochim Biophys Acta       Date:  2007-07-19

7.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

8.  Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells.

Authors:  Donavon C Hiss; Gary A Gabriels; Peter I Folb
Journal:  Cancer Cell Int       Date:  2007-04-18       Impact factor: 5.722

9.  Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase.

Authors:  K M Nicholson; D M Quinn; G L Kellett; J R Warr
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

Authors:  P Heffeter; M A Jakupec; W Körner; P Chiba; C Pirker; R Dornetshuber; L Elbling; H Sutterlüty; M Micksche; B K Keppler; W Berger
Journal:  Biochem Pharmacol       Date:  2007-03-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.